( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57



Misra S.*, Kaushal J. and Khurana A. K.


Introduction: Dry eye disease is defined as a multifactorial disease of tears and ocular surface that results in symp-toms of discomfort, visual disturbance and tear film instability. This study was done to observe improvement in quality of life of loteprednol versus cyclosporine A as an add on therapy to carboxymethyl cellulose (CMC) versus CMC alone in dry eye disease patients. Materials & Methods: A prospective, randomized, comparative clinical study was conducted on 60 patients and they were randomly divided in three groups of 20 each. Group A: CMC 1% 6 times a day as monotherapy, Group B: CMC 1% 6 times a day and loteprednol 0.5% 4 times a day and Group C: CMC 1% 6 times a day and cyclosporine A 0.5% 4 times a day for a period of 8 weeks. Quality of life assess-ment was done by ocular surface disease index (O.S.D.I) and Likert scale. Results: On intragroup analysis, O.S.D.I score in group A, B and C there was decrease in score by 7.94, 11.78 and 15.4 respectively at the end of 2 weeks compared to their baseline values (p<0.05). At the end of 8 weeks in group A, B and C there was still reduction of score by 33.5, 39.04 and 38.64 respectively compared to their baseline values (p< 0.05). On intergroup analysis, at the end of 2 weeks, statistically significant better response was seen with group B and C as compared to group A which continued till the end of 8 weeks. When group B and C were compared with each other, better response was seen with group B which continued till the end of 8 weeks. In likert scale, patients were asked to evaluate the relief according to five level Likert item e.g Strongly agree, Agree, Neither agree nor disagree (Neutral), Disagree, Strongly disagree. More patients agreed for relief of symptoms with CMC plus lotedrednol as compared to CMC plus cyclosporine A and CMC as mono therapy but the difference was not statistically significant. Discussion: Loteprednol plus CMC showed more improvement in quality of life than other two groups in both parameters. None of the studies could be found where similar schedules were compared to observe these effects.

Keywords: Carboxymethyl cellulose, loteprednol, ocular surface disease index, cyclosporine A.

[Full Text Article]



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 November 2021 Issue has been Published, Kindly check it on


    NOVEMBER Issue has been successfully launched on 1 November 2021.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI )